Document Detail

Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
MedLine Citation:
PMID:  6412535     Owner:  NLM     Status:  MEDLINE    
Gated cardiac scanning was used to evaluate the hemodynamic effects of encainide in 19 patients (1 woman) with complex ventricular arrhythmia and depressed left ventricular (LV) function (ejection fraction less than 45%). Patients were 36 to 80 years old (average 61). All were candidates for long-term encainide therapy after having failed with currently available antiarrhythmics. Sixty-three percent had congestive heart failure before they received encainide. All were evaluated in the hospital before encainide therapy by a gated cardiac scan performed at least 3 days after discontinuing all antiarrhythmic drugs. Patients received oral encainide in doses of 75 to 200 mg. Gated cardiac scans were repeated 1 to 2 weeks later when an 80% reduction in frequency of premature ventricular complexes was observed on a 24-hour Holter recording. No patient had worsening of congestive heart failure during encainide therapy. Encainide did not significantly affect ejection fraction, which averaged 22 +/- 10% before and 25 +/- 14% (SD) after encainide (difference not significant [NS]). Other hemodynamic variables, including heart rate, blood pressure, stroke volume and end-diastolic volume, remained unchanged during encainide therapy. Digoxin blood levels in 10 patients averaged 1.04 +/- 0.43 before and 1.22 +/- 0.47 mg/ml (NS) during encainide therapy. Thus, encainide given orally in clinically effective doses does not appear to have significant hemodynamic effects in patients with ventricular arrhythmia and depressed LV function.
M H Sami; V A Derbekyan; R Lisbona
Related Documents :
2642755 - Arterial baroreflex abnormalities in heart failure. reversal after orthotopic cardiac t...
8840375 - Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report ...
3403095 - Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
3035525 - Treatment of congestive heart failure. pathophysiologic and pharmacologic concepts.
21160605 - Hypertrophic cardiomyopathy and sudden cardiac death.
16955815 - Echocardiographic assessment of the left ventricular outflow tract in the boxer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  52     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1983 Sep 
Date Detail:
Created Date:  1983-10-08     Completed Date:  1983-10-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  507-11     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anilides / therapeutic use*
Anti-Arrhythmia Agents / therapeutic use*
Arrhythmias, Cardiac / drug therapy*,  radionuclide imaging
Blood Pressure / drug effects
Digoxin / blood
Heart / radionuclide imaging
Heart Rate / drug effects
Hemodynamics / drug effects*
Middle Aged
Stroke Volume / drug effects
Technetium / diagnostic use
Reg. No./Substance:
0/Anilides; 0/Anti-Arrhythmia Agents; 20830-75-5/Digoxin; 66778-36-7/Encainide; 7440-26-8/Technetium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy.
Next Document:  Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide (MAC) in stage III and I...